Skip to main content

Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data Cover

.blurhash-client-img { display: none !important; }

Adjuvant nivolumab in resected oesophageal or gastroesophageal junction cancer following neoadjuvant chemoradiotherapy: Slovenian real-world data

Radiology and Oncology

By: Nezka Hribernik, Rozala Arko, Gorana Gasljevic and Martina Rebersek

Open Access

|Apr 2026

Figures & tables

Authors

Nezka Hribernik

nhribernik@onko-i.si

Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Rozala Arko

Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Gorana Gasljevic

Department of Pathology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Maribor, Maribor, Slovenia

Martina Rebersek

mrebersek@onko-i.si

Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia

Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia

Articles in this issue

DOI: https://doi.org/10.2478/raon-2026-0020 | Journal eISSN: 1581-3207 | Journal ISSN: 1318-2099

Journal RSS Feed

Language: English

Submitted on: Oct 2, 2025

|

Accepted on: Dec 2, 2026

|

Published on: Apr 16, 2026

Published by: Association of Radiology and Oncology

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

oesophageal and gastroesophageal junction cancer,

adjuvant immunotherapy,

Related subjects:

Clinical medicine,

Internal medicine,

Haematology, oncology,

© 2026 Nezka Hribernik, Rozala Arko, Gorana Gasljevic, Martina Rebersek, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution 4.0 License.